Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review

NİNO, Fabio Mayorga; ALVARADO, Nelson Camilo Gutierrez

doi:10.14744/ejmo.2019.46574

Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review

Fabio Mayorga NİNO, (Health Sciences Universidad Pedagógica y Tecnológica de Colombia, Faculty of Medicine, Department of Pharmacology, Tunja, Colombia)

Nelson Camilo Gutierrez ALVARADO (Universidad Pedagógica y Tecnológica de Colombia, Department of Pharmacology, Tunja, Colombia)

Eurasian Journal of Medicine and Oncology

1 0

Yıl: 2019 Cilt: 3 Sayı: 2 Sayfa Aralığı: 77 - 91 Metin Dili: İngilizce DOI: 10.14744/ejmo.2019.46574 İndeks Tarihi: 22-04-2020

Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review

Öz:

Cancer is a complex pathophysiological condition that produces an important number of death around the world.At present, there are different ways to treat cancer: chemotherapy, radiotherapy and surgery. Cancer chemotherapyused today in many cases is effective, but it is very toxic too. The endocannabinoid system is implicated in a varietyof physiological and pathological processes, including cancer. Many studies have shown, since 1975, that both phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) offer an antioneoplastic activity. Latter, other researchers have displayed that endocannabinoids as anandamide (ANA) and 2-arachidonoylglycerol (2-AG) alsopresent the same potential activity. Phytocannabinoids and endocannabinoids act through CB1 and CB2 receptors toproduce that effect. However, THC -the main phytocannabinoid presenting anticancer action- as well as anandamideemployed in pharmacological doses, produce important phycotropic effects, but these cannabinoid compounds donot produce major adverse reactions like conventional antineoplastic drugs. On this basis, scientists have to developanalogs or derivatives of cannabinoids/endocannabinoids that cannot induce psychotropic effects. It is important tostudy more deeply chronopharmacological aspects of cannabinoids/endocannabinoids in cancer therapy, althoughsome is known today.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Hermanson DJ, Marnett LJ. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev 2011;30:599–612.
2. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602.
3. Burstein S, Salmonsen R. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg Med Chem 2008;16:9644–51.
4. Vaughn LK, Denning G, Stuhr KL, de Wit H, Hill MN, Hillard CJ. Endocannabinoid signalling: has it got rhythm? Br J Pharmacol 2010;160:530–43.
5. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547–50.
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–4.
7. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–5.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–9.
9. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR,et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50:83–90.
10. Farrell EK, Merkler DJ. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 2008;13:558–68.
11. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res 2016;62:107–28.
12. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 2009;89:112–9.
13. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 2011;163:1447–63.
14. Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol Biochem Behav 2008;90:501–11.
15. Flygare J, Sander B. The endocannabinoid system in cancerpotential therapeutic target? Semin Cancer Biol 2008;18:176– 89.
16. Mayorga NF, CÁRDENAS RHS. Endocannabinoids: A therapeutic option to cancer treatment. [Article in Spanish] Vitae 2009;16:259–67.
17. Taylor AH, Amoako AA, Bambang K, Karasu T, Gebeh A, Lam PM, et al. Endocannabinoids and pregnancy. Clin Chim Acta 2010;411:921–30.
18. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009;60:77– 84.
19. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003;163:463–8.
20. Baggelaar MP, van Esbroeck AC, van Rooden EJ, Florea BI, Overkleeft HS, Marsicano G, et al. Chemical Proteomics Maps Brain Region Specific Activity of Endocannabinoid Hydrolases. ACS Chem Biol 2017;12:852–61.
21. Guindon J. A novel inhibitor of endocannabinoid catabolic enzymes sheds light on behind the scene interplay between chronic pain, analgesic tolerance, and heroin dependence. Neuropharmacology 2017;114:168–71.
22. Moreno E, Chiarlone A, Medrano M, Puigdellívol M, Bibic L, Howell LA, et al. Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum. Neuropsychopharmacology 2018;43:964–77.
23. Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 2011;15:297–308.
24. Wheal AJ, Bennett T, Randall MD, Gardiner SM. Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 2007;152:717–24.
25. Von Der Haar J, Talebi S, Ghobadi F, Singh S, Chirurgi R, Rajeswari P, et al. Synthetic Cannabinoids and Their Effects on the Cardiovascular System. J Emerg Med 2016;50:258–62.
26. Li MH, Suchland KL, Ingram SL. Compensatory Activation of Cannabinoid CB2 Receptor Inhibition of GABA Release in the Rostral Ventromedial Medulla in Inflammatory Pain. J Neurosci 2017;37:626–36.
27. Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, Welch SP. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9-tetrahydrocannabinol. Eur J Pharmacol 2006;539:57–63.
28. Ottani A, Leone S, Sandrini M, Ferrari A, Bertolini A. The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol 2006;531:280–1.
29. Katz PS, Sulzer JK, Impastato RA, Teng SX, Rogers EK, Molina PE. Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma 2015;32:297–306.
30. Baron EP. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Headache 2015;55:885–916.
31. Achiron A, Miron S, Lavie V, Margalit R, Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000;102:26–31.
32. Notcutt WG. Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 2015;12:769–77.
33. Fagan SG, Campbell VA. The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 2014;171:1347–60.
34. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord 2015;30:313–27.
35. Rueda-Orozco PE, Soria-Gomez E, Montes-Rodriguez CJ, Martínez-Vargas M, Galicia O, Navarro L, et al. A potential function of endocannabinoids in the selection of a navigationstrategy by rats. Psychopharmacology (Berl) 2008;198:565–76.
36. Koch M, Ferreirós N, Geisslinger G, Dehghani F, Korf HW. Rhythmic control of endocannabinoids in the rat pineal gland. Chronobiol Int 2015;32:869–74.
37. Atkinson HC, Leggett JD, Wood SA, Castrique ES, Kershaw YM, Lightman SL. Regulation of the hypothalamic-pituitary-adrenal axis circadian rhythm by endocannabinoids is sexually diergic. Endocrinology 2010;151:3720–7.
38. Murillo-Rodríguez E, Machado S, Rocha NB, Budde H, Yuan TF, Arias-Carrión O. Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis. Neuroscience 2016;339:433–49.
39. Murillo-Rodríguez E, Millán-Aldaco D, Di Marzo V, DruckerColín R. The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience 2008;157:1–11.
40. Brunton LL, Dandan RH. Goodman and Gilman's Manual of Pharmacology and Therapeutics. 2nd ed. McGraw-Hill Education; 2013.
41. Chandrasekaran G, Tátrai P, Gergely F. Hitting the brakes: targeting microtubule motors in cancer. Br J Cancer 2015;113:693–8.
42. Hilal-Dandan R, Brunton L. Goodman and Gilman manual of pharmacology and therapeutics: McGraw Hill Professional; 2013.
43. Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Cancer 2013;119:665–71.
44. Koziolova E, Janouskova O, Chytil P, Studenovsky M, Kostka L, Etrych T. Nanotherapeutics with anthracyclines: methods of determination and quantification of anthracyclines in biological samples. Physiol Res 2015;64 Suppl 1:S1–10.
45. Fouillaud M, Venkatachalam M, Girard-Valenciennes E, Caro Y, Dufossé L. Anthraquinones and Derivatives from Marine-Derived Fungi: StructuralDiversity and Selected Biological Activities. Mar Drugs 2016;14.
46. Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma 2015;56:2273–80.
47. Chen R, Sanchez J, Rosen ST. Clinical Management Updates in Mantle Cell Lymphoma. Oncology (Williston Park) 2016;30:353–60.
48. Park JY, Nam JH. Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer. Oncologist 2015;20:270–8.
49. Yasuda MT, Sakakibara H, Shimoi K. Estrogen- and stress-induced DNA damage in breast cancer and chemoprevention with dietary flavonoid. Genes Environ 2017;39:10.
50. Singh A, Xu YJ. The Cell Killing Mechanisms of Hydroxyurea. Genes (Basel) 2016;7. pii: E99.
51. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist 2016;21:1471–82.
52. Elgemeie GH, Salah AM, Abbas NS, Hussein HA, Mohamed RA. Pyrimidine non-nucleoside analogs: A direct synthesis of a novel class of N-substituted amino and Nsulfonamide derivatives of pyrimidines. Nucleosides Nucleotides Nucleic Acids 2017;36:213–23.
53. Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factorreceptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther 2016;12:131–37.
54. Wehrli M, Oppliger Leibundgut E, Gattiker HH, Manz MG, Müller AM, et al. Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110- FGFR1 Rearrangement. Oncologist 2017;22:480–83.
55. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, et al. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol 2017;35:1231–9.
56. de Oliveira Taveira M, Nabavi S, Wang Y, Tonellato P, Esteva FJ, Cantley LC, et al. Genomic characteristics of trastuzumabresistant Her2-positive metastatic breast cancer. J Cancer Res Clin Oncol 2017;143:1255–62.
57. Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, et al. Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma". Mol Ther 2016;24:2033
58. Li B, Gao N, Zhang Z, Chen QM, Li LJ, Li Y. Historical and Clinical Experiences of Gene Therapy for Solid Cancers in China. Genes (Basel) 2017;8. pii: E85.
59. Rocha FC, Dos Santos Júnior JG, Stefano SC, da Silveira DX. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas. J Neurooncol 2014;116:11–24.
60. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, et al. Cannabidiol enhances the inhibitory effects of delta9- tetrahydrocannabinolon human glioblastoma cell proliferation and survival. Mol Cancer Ther 2010;9:180–9.
61. Khan MI, Sobocińska AA, Czarnecka AM, Król M, Botta B, Szczylik C. The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancerand their Development: From Nature to Laboratory. Curr Pharm Des 2016;22:1756–66.
62. Javid FA, Phillips RM, Afshinjavid S, Verde R, Ligresti A. Cannabinoid pharmacology in cancer research: A new hope for cancer patients? Eur J Pharmacol 2016;775:1–14.
63. Birdsall SM, Birdsall TC, Tims LA. The Use of Medical Marijuana in Cancer. Curr Oncol Rep 2016;18:40.
64. Pisanti S, Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 2009;60:107–16.
65. Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treat Rev 2012;38:911–8.
66. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growthand metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003;17:1771–3.
67. Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart JP. Antiproliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003;56:1–12.
68. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasionof prostate cancer cells. Biochem Biophys Res Commun 2005;332:1028–33.
69. Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, GalveRoperh I, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95:197–203.
70. Rodrigues LC, Gobira PH, de Oliveira AC, Pelição R, Teixeira AL, Moreira FA, et al. Neuroinflammation as a possible link between cannabinoids and addiction. Acta Neuropsychiatr 2014;26:334–46.
71. Tegeder I. Endocannabinoids as Guardians of Metastasis. Int J Mol Sci 2016;17:230.

APA	NİNO F, ALVARADO N (2019). Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. , 77 - 91. 10.14744/ejmo.2019.46574
Chicago	NİNO Fabio Mayorga,ALVARADO Nelson Camilo Gutierrez Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. (2019): 77 - 91. 10.14744/ejmo.2019.46574
MLA	NİNO Fabio Mayorga,ALVARADO Nelson Camilo Gutierrez Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. , 2019, ss.77 - 91. 10.14744/ejmo.2019.46574
AMA	NİNO F,ALVARADO N Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. . 2019; 77 - 91. 10.14744/ejmo.2019.46574
Vancouver	NİNO F,ALVARADO N Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. . 2019; 77 - 91. 10.14744/ejmo.2019.46574
IEEE	NİNO F,ALVARADO N "Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review." , ss.77 - 91, 2019. 10.14744/ejmo.2019.46574
ISNAD	NİNO, Fabio Mayorga - ALVARADO, Nelson Camilo Gutierrez. "Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review". (2019), 77-91. https://doi.org/10.14744/ejmo.2019.46574

APA	NİNO F, ALVARADO N (2019). Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology, 3(2), 77 - 91. 10.14744/ejmo.2019.46574
Chicago	NİNO Fabio Mayorga,ALVARADO Nelson Camilo Gutierrez Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology 3, no.2 (2019): 77 - 91. 10.14744/ejmo.2019.46574
MLA	NİNO Fabio Mayorga,ALVARADO Nelson Camilo Gutierrez Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology, vol.3, no.2, 2019, ss.77 - 91. 10.14744/ejmo.2019.46574
AMA	NİNO F,ALVARADO N Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 77 - 91. 10.14744/ejmo.2019.46574
Vancouver	NİNO F,ALVARADO N Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review. Eurasian Journal of Medicine and Oncology. 2019; 3(2): 77 - 91. 10.14744/ejmo.2019.46574
IEEE	NİNO F,ALVARADO N "Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review." Eurasian Journal of Medicine and Oncology, 3, ss.77 - 91, 2019. 10.14744/ejmo.2019.46574
ISNAD	NİNO, Fabio Mayorga - ALVARADO, Nelson Camilo Gutierrez. "Cannabinoids/Endocannabinoids as Possible Antineoplastic Therapy in Comparisson to Cancer Pharmacological Treatments Used Today: Narrative Review". Eurasian Journal of Medicine and Oncology 3/2 (2019), 77-91. https://doi.org/10.14744/ejmo.2019.46574